We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The Immunogenicity of a Foot-and-Mouth Disease Virus Serotype O Vaccine in Commercial and Subsistence Cattle Herds in Zambia.
- Authors
Banda, Frank; Ludi, Anna B.; Wilsden, Ginette; Browning, Clare; Kangwa, Henry L.; Mooya, Lynnfield; Ngoma, Masuzyo; Muuka, Geoffrey M.; Mundia, Cornelius; Fandamu, Paul; Paton, David J.; King, Donald P.; Quan, Melvyn
- Abstract
The recent introduction of foot-and-mouth disease (FMD) virus serotype O (O/EA-2 topotype) in Southern Africa has changed the epidemiology of the disease and vaccine requirements of the region. Commercial and subsistence cattle herds in Zambia were vaccinated with an FMD virus serotype O Manisa vaccine according to a double- or single-dose vaccination schedule. Heterologous antibody responses induced by this vaccine against a representative O/EA-2 virus from Zambia were determined. Virus neutralisation tests (VNTs) showed double-dosed cattle had a mean reciprocal log virus neutralisation titre of 2.02 (standard error [SE] = 0.16, n = 9) for commercial herds and 1.65 (SE = 0.17, n = 5) for subsistence herds 56 days after the first vaccination (dpv). Significantly lower mean titres were observed for single-dosed commercial herds (0.90, SE = 0.08, n = 9) and subsistence herds (1.15, SE = 0.18, n = 3) 56 dpv. A comparison of these results and those generated by solid-phase competitive ELISA (SPCE) tests showed a statistically significant positive correlation by Cohen's kappa coefficient. Therefore, SPCE might be used in assessing the immunogenicity of vaccines in place of VNT. Furthermore, for this vaccine and field strain, a vaccination regime employing a two-dose primary course and revaccination after 4–6 months is likely to be appropriate.
- Subjects
ZAMBIA; ANIMAL herds; FOOT &; mouth disease; CATTLE herding; IMMUNE response; VIRUS diseases
- Publication
Vaccines, 2023, Vol 11, Issue 12, p1818
- ISSN
2076-393X
- Publication type
Article
- DOI
10.3390/vaccines11121818